Stem Cell Treatments Around the World: Boon or Bane?

  • Alok Srivastava
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)


Stem cell-based therapies hold immense possibilities for treating ­diseases. While responsible scientists and physicians attempt to develop such treatments in a scientific and ethical manner, many others around the world are already offering unproven therapies for a wide range of diseases. Interestingly, they often use cells that have been known and accessible for decades. It has resulted in large numbers of vulnerable patients being exploited around the world. This chapter will address the reasons for this phenomenon, the impact that it has had on the field, the harm that can come from them, and the potential solutions to this problem.


Stem Cell Adult Stem Cell Stem Cell Research Medical Tourism Embryonic Stem Cell Research 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schwartz RS (2006) The politics and promise of stem-cell research. N Engl J Med 355(12):1189–1191PubMedCrossRefGoogle Scholar
  2. 2.
    Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, De Luca M, Fox IJ, Gerstle C, Goldstein RA, Hermerén G, High KA, Kim HO, Lee HP, Levy-Lahad E, Li L, Lo B, Marshak DR, McNab A, Munsie M, Nakauchi H, Rao M, Rooke HM, Valles CS, Srivastava A, Sugarman J, Taylor PL, Veiga A, Wong AL, Zoloth L, Daley GQ (2008) New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 3(6):607–609PubMedCrossRefGoogle Scholar
  3. 3.
    Sancho-Bru P, Najimi M, Caruso M, Pauwelyn K, Cantz T, Forbes S, Roskams T, Ott M, Gehling U, Sokal E, Verfaillie CM, Muraca M (2009) Stem and progenitor cells for liver repopulation: can we standardise the process from bench to bedside? Gut 58(4):594–603PubMedCrossRefGoogle Scholar
  4. 4.
    Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T (2008) Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3(6):591–594PubMedCrossRefGoogle Scholar
  5. 5.
    Song P (2010) Biotech pilgrims and the transnational quest for stem cell cures. Med Anthropol 29(4):384–402PubMedCrossRefGoogle Scholar
  6. 6.
    Ryan KA, Sanders AN, Wang DD, Levine AD (2010) Tracking the rise of stem cell tourism. Regen Med 5(1):27–33PubMedCrossRefGoogle Scholar
  7. 7.
    Gill JS, Johnston O (2007) Access to kidney transplantation: the limitations of our current understanding. J Nephrol 20(5):501–506PubMedGoogle Scholar
  8. 8.
    Joseph S (2003) Pharmaceutical corporations and access to drugs: the “fourth wave” of corporate human rights scrutiny. Hum Rights Q 25:425–452CrossRefGoogle Scholar
  9. 9.
    Devereaux M, Loring JF (2010) Growth of an industry: how U.S. scientists and clinicians have enabled stem cell tourism. Am J Bioeth 10:45–46PubMedGoogle Scholar
  10. 10.
    World program for action concerning disabled persons. Accessed 25 June 2012
  11. 11.
    Cohen DE, Melton D (2011) Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet 12(4):243–252PubMedCrossRefGoogle Scholar
  12. 12.
    Daley GQ, Ahrlund Richter L, Auerbach JM, Benvenisty N, Charo RA, Chen G, Deng HK, Goldstein LS, Hudson KL, Hyun I, Junn SC, Love J, Lee EH, McLaren A, Mummery CL, Nakatsuji N, Racowsky C, Rooke H, Rossant J, Schöler HR, Solbakk JH, Taylor P, Trounson AO, Weissman IL, Wilmut I, Yu J, Zoloth L (2007) Ethics. The ISSCR guidelines for human embryonic stem cell research. Science 315(5812):603–604PubMedCrossRefGoogle Scholar
  13. 13.
    Tögel F, Westenfelder C (2007) Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn 236(12):3321–3331PubMedCrossRefGoogle Scholar
  14. 14.
    Wagers AJ, Weissman IL (2004) Plasticity of adult stem cells. Cell 116(5):639–648PubMedCrossRefGoogle Scholar
  15. 15.
    Thomas ED (1995) Bone marrow transplantation from bench to bedside. Ann N Y Acad Sci 770:34–41PubMedCrossRefGoogle Scholar
  16. 16.
    Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N, Grünwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM (2002) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106(24):3009–3017PubMedCrossRefGoogle Scholar
  17. 17.
    Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M (2003) Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422(6934):897–901PubMedCrossRefGoogle Scholar
  18. 18.
    Jiang S, Walker L, Afentoulis M, Anderson DA, Jauron-Mills L, Corless CL, Fleming WH (2004) Transplanted human bone marrow contributes to vascular endothelium. Proc Natl Acad Sci USA 101(48):16891–16896PubMedCrossRefGoogle Scholar
  19. 19.
    Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K (2006) Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355(12):1199–1209PubMedCrossRefGoogle Scholar
  20. 20.
    Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM, REPAIR-AMI Investigators (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355(12):1210–1221PubMedCrossRefGoogle Scholar
  21. 21.
    Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM (2006) Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355(12):1222–1232PubMedCrossRefGoogle Scholar
  22. 22.
    Barry FP, Murphy JM (2004) Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 36(4):568–584PubMedCrossRefGoogle Scholar
  23. 23.
    Sotiropoulou PA, Perez SA, Papamichail M (2007) Clinical grade expansion of human bone marrow mesenchymal stem cells. Methods Mol Biol 407:245–263PubMedCrossRefGoogle Scholar
  24. 24.
    Chamberlain G, Fox J, Ashton B, Middleton J (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25(11):2739–2749PubMedCrossRefGoogle Scholar
  25. 25.
    Covas DT, Panepucci RA, Fontes AM, Silva WA Jr, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 36(5):642–654PubMedCrossRefGoogle Scholar
  26. 26.
    Wagner J, Kean T, Young R, Dennis JE, Caplan AI (2009) Optimizing mesenchymal stem cell-based therapeutics. Curr Opin Biotechnol 20(5):531–536PubMedCrossRefGoogle Scholar
  27. 27.
    Trouvin JH, Flory E, Tsiftsoglou A, Sarkadi B, Gudmundsson K, O’Donovan M, Migliaccio G, Ancāns J, Maciulaitis R, Robert JL, Samuel A, Ovelgönne JH, Hystad M, Fal AM, Lima BS, Moraru AS, Turcáni P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schüssler-Lenz M, Kokkas V, Buzás Z, MacAleenan N, Galli MC, Linē A, Gulbinovic J, Berchem G, Fraczek M, Menezes-Ferreira M, Vilceanu N, Hrubisko M, Marinko P, Timón M, Cheng W, Crosbie GA, Meade N, di Paola ML, VandenDriessche T, Ljungman P, D’Apote L, Oliver-Diaz O, Büttel I, Celis P (2010) Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9(3):195–201PubMedCrossRefGoogle Scholar
  28. 28.
    Cuende N, Izeta A (2010) Clinical translation of stem cell therapies: a bridgeable gap. Cell Stem Cell 6(6):508–512PubMedCrossRefGoogle Scholar
  29. 29.
    Trounson A, Baum E, Gibbons D, Tekamp-Olson P (2010) Developing a case study model for successful translation of stem cell therapies. Cell Stem Cell 6(6):513–516PubMedCrossRefGoogle Scholar
  30. 30.
    Giordano A, Galderisi U, Marino IR (2007) From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 211(1):27–35PubMedCrossRefGoogle Scholar
  31. 31.
    Hansson M, Madsen OD (2010) Pluripotent stem cells, a potential source of beta-cells for diabetes therapy. Curr Opin Investig Drugs 11(4):417–425PubMedGoogle Scholar
  32. 32.
    Herberts CA, Kwa MS, Hermsen HP (2011) Risk factors in the development of stem cell therapy. J Transl Med 9Google Scholar
  33. 33.
    Hyun I (2010) Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges. J Law Med Ethics 38(2):277–285PubMedCrossRefGoogle Scholar
  34. 34.
    Lindvall O, Hyun I (2009) Medical innovation versus stem cell tourism. Science 324(5935):1664–1665PubMedCrossRefGoogle Scholar
  35. 35.
    Davison AC (2010) Brave pioneers or clinical cowboys? Cell Stem Cell 6(6):504–505PubMedCrossRefGoogle Scholar
  36. 36.
    Murdoch CE, Scott CT (2010) Stem cell tourism and the power of hope. Am J Bioeth 10(5):16–23PubMedCrossRefGoogle Scholar
  37. 37.
    Caplan A, Levine B (2010) Hope, hype and help: ethically assessing the growing market in stem cell therapies. Am J Bioeth 10(5):24–25PubMedCrossRefGoogle Scholar
  38. 38.
    Taylor PL, Barker RA, Blume KG, Cattaneo E, Colman A, Deng H, Edgar H, Fox IJ, Gerstle C, Goldstein LS, High KA, Lyall A, Parkman R, Pitossi FJ, Prentice ED, Rooke HM, Sipp DA, Srivastava A, Stayn S, Steinberg GK, Wagers AJ, Weissman IL (2010) Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell 7(1):43–49PubMedCrossRefGoogle Scholar
  39. 39.
    McMahon DS, Thorsteinsdóttir H, Singer PA, Daar AS (2010) Cultivating regenerative medicine innovation in China. Regen Med 5(1):35–44PubMedCrossRefGoogle Scholar
  40. 40.
    Cohen CB, Cohen PJ (2010) International stem cell tourism and the need for effective regulation. Part I: stem cell tourism in Russia and India: clinical research, innovative treatment, or unproven hype? Kennedy Inst Ethics J 20(1):27–49PubMedCrossRefGoogle Scholar
  41. 41.
    Alleman BW, Luger T, Reisinger HS, Martin R, Horowitz MD, Cram P (2011) Medical tourism services available to residents of the United States. J Gen Intern Med 26(5):492–497PubMedCrossRefGoogle Scholar
  42. 42.
    Zarzeczny A, Caulfield T (2010) Stem cell tourism and doctors’ duties to minors – a view from Canada. Am J Bioeth 10(5):3–15PubMedCrossRefGoogle Scholar
  43. 43.
    Hyun I (2010) The bioethics of stem cell research and therapy. J Clin Invest 120(1):71–75PubMedCrossRefGoogle Scholar
  44. 44.
    Fowler HL (2004) Misapplied ethical considerations: U.S. Federal stem cell mandates lack global focus and market foresight. Cornell Int Law J 36(3):521–544PubMedGoogle Scholar
  45. 45.
    Turner L (2010) “Medical tourism” and the global marketplace in health services: U.S. patients, international hospitals, and the search for affordable health care. Int J Health Serv 40(3):443–467PubMedCrossRefGoogle Scholar
  46. 46.
    MacReady N (2009) The murky ethics of stem-cell tourism. Lancet Oncol 10(4):317–318PubMedCrossRefGoogle Scholar
  47. 47.
    Barclay E (2009) Stem-cell experts raise concerns about medical tourism. Lancet 373(9667):883–884PubMedCrossRefGoogle Scholar
  48. 48.
    Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G (2009) Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6(2):e1000029PubMedCrossRefGoogle Scholar
  49. 49.
    Cyranoski D (2010) Korean deaths spark inquiry. Nature 468(7323):485PubMedCrossRefGoogle Scholar
  50. 50.
    Cyranoski D (2010) Strange lesions after stem-cell therapy. Nature 465(7301):997PubMedCrossRefGoogle Scholar
  51. 51.
    Sipp D (2010) Hope alone is not an outcome: why regulations makes sense for the global stem cell industry. Am J Bioeth 10(5):33–34PubMedCrossRefGoogle Scholar
  52. 52.
    Dolan T (2010) A three-pronged management strategy to stem cell tourism. Am J Bioeth 10(5):43–45PubMedCrossRefGoogle Scholar
  53. 53.
    Shalev C (2010) Stem cell tourism – a challenge for trans-national governance. Am J Bioeth 10(5):40–42PubMedCrossRefGoogle Scholar
  54. 54.
    Cyranoski D (2012) China’s stem cell rules go unheeded. Nature 484:149–150PubMedCrossRefGoogle Scholar
  55. 55.
    Cohen CB, Cohen PJ (2010) International stem cell tourism and the need for effective regulation – part II: developing sound oversight measures and effective patient support. Kennedy Inst Ethics J 20(3):207–230PubMedCrossRefGoogle Scholar
  56. 56.
    Crozier GK, Thomsen K (2010) Stem cell tourism and the role of health professional organizations. Am J Bioeth 10(5):36–38PubMedCrossRefGoogle Scholar
  57. 57.
    Evans R, Kotchetkova I, Langer S (2009) Just around the corner: rhetorics of progress and promise in genetic research. Public Underst Sci 18(1):43–59PubMedCrossRefGoogle Scholar
  58. 58.
    Peddie VL, Porter M, Counsell C, Caie L, Pearson D, Bhattacharya S (2009) ‘Not taken in by media hype’: how potential donors, recipients and members of the general public perceive stem cell research. Hum Reprod 24(5):1106–1113PubMedCrossRefGoogle Scholar
  59. 59.
    Michelle C (2006) Media(ted) fabrications: how the science-media symbiosis helped ‘sell’ cord banking. Commun Med 3(1):55–68PubMedCrossRefGoogle Scholar
  60. 60.
    McIntosh K (2005) Exaggerated claims of cures threaten stem cell research. BMJ 330(7503):1285PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Haematology and Centre for Stem Cell ResearchChristian Medical CollegeVelloreIndia

Personalised recommendations